Corynebacterium amycolatum

Corynebacterium amycolatum is a Gram-positive, non-spore-forming, aerobic or facultatively anaerobic bacillus capable of fermentation with propionic acid as the major end product of its glucose metabolism. One of its best known relatives is "Corynebacterium diphtheriae", the causative agent of diphtheria. "C. amycolatum" is a common component of the natural flora found on human skin and mucous membranes, and as such, is often disregarded by physicians as a contaminant when found in blood cultures. However, "C. amycolatum" is actually an opportunistic pathogen capable of causing serious human disease such as endocarditis and sepsis.
Identification.
First described in 1988, "C. amycolatum" is one of the diphtheroids most often isolated from clinical samples. However, it is often difficult to differentiate from other fermentative corynebacteria such as "C. minutissimum" and "C. xerosis", both of which are known human pathogens. One method of differentiation, however, is by observing the cell wall. Unlike other members of this genus, "C. amycolatum" lacks mycolic acid, long fatty acids usually found in the cell wall. "C. amycolatum" also differs in its colony morphology; the species characteristically produces flat, whitish-gray, matte or waxy colonies on Schaedler blood agar. Its antibiotic sensitivity may also aid in its identification; the organism is generally resistant to multiple antibiotics. Because of its relatively new status as a pathogen, however, no standard laboratory tests yet identify "C. amycolatum".
Disease.
"C. amycolatum" has been shown to cause pneumonia, peritonitis, empyema, infectious endocarditis, and fatal sepsis, most of which occur as nosocomial infections. As an opportunistic pathogen, the bacterium is pathogenic in immunocompromised patients, mostly infecting those with underlying heart defects or intravascular devices. "Corynebacterium" endocarditis usually infects the left side of the heart in males, though "C. amycolatum" has shown a predilection for women. While cases of disease have been small in number, this underreporting could be due to misdiagnosis of "C. amycolatum" as "C. xerosis", which is a known human pathogen.
Treatment.
For the few cases thus far, vancomycin or daptomycin has been used in tandem with rifampicin for a duration ranging from four weeks to six months. Valve replacement was also required in some cases of infectious endocarditis. Due to its recent pathogenic status, however, few treatments have been tested, and an optimal treatment regimen has yet to be established.
Antibiotic resistance.
One of "C. amycolatum's" characteristic traits is its resistance to a wide range of antibiotics. Various strains tested have shown resistance to beta lactam antibiotics, lincosamides, macrolides, and quinolones. Multiple drug-resistant strains were mainly isolated from wounds of patients treated in departments of general surgery and vascular surgery. However, the bacterium was shown to be particularly sensitive to glycopeptide and lipopeptide antibiotics.